Related Experiment Video

Updated: Aug 25, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation

Emiliano Giostra1, Gerd A Kullak-Ublick, Walter Keller

  • 1Division of Gastroenterology and Hepatology, University Hospital of Geneva, rue Micheli-du-Crest 24, 1211 Geneva, Switzerland.

Transplant International : Official Journal of the European Society for Organ Transplantation
|April 3, 2004
PubMed

Insights

Hepatitis C virus (HCV) recurrence post-liver transplant (LT) is common. Ribavirin and interferon-alpha (IFN-alpha) therapy can lead to sustained virological response in some patients, improving liver inflammation.

Area of Science:

  • Hepatology
  • Virology
  • Transplantation Medicine

Background:

  • Hepatitis C virus (HCV) infection frequently recurs after liver transplantation (LT).
  • Graft hepatitis sequels are a major cause of morbidity and mortality in LT recipients.
  • Effective management of recurrent HCV post-LT is crucial.

Purpose of the Study:

  • To evaluate the efficacy of sequential ribavirin and interferon-alpha (IFN-alpha) therapy for recurrent Hepatitis C virus (HCV) infection after liver transplantation (LT).

Main Methods:

  • An uncontrolled trial involving 31 patients with histologically confirmed recurrent HCV post-LT.
  • Sequential therapy: 12 weeks of ribavirin, followed by 48 weeks of ribavirin plus IFN-alpha.
  • Intent-to-treat analysis to assess viral load and sustained response.

Main Results:

  • Sustained virological response (undetectable HCV RNA 24 weeks post-treatment) was achieved in 29% of patients (9/31).
  • Sustained responders showed significant improvement in liver inflammatory activity scores.
  • Sustained response correlated with treatment duration, not HCV genotype or baseline viral load.

Conclusions:

  • Ribavirin/IFN-alpha therapy may benefit patients with recurrent HCV post-LT.
  • Treatment tolerance and sufficient duration are key factors for achieving sustained virological response.
  • Further research into optimizing treatment duration and regimens is warranted.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...